Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umeta-Miyue
- Development stage
- Phase 4
- Lead developer
- BGI Genomics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Umeta-Miyue is an oral probiotic formulation containing two specific strains of lactic acid bacteria: *Lactobacillus rhamnosus* GR-1 and *Lactobacillus reuteri* RC-14. Developed and marketed by BGI Genomics under the Umeta brand, this product is designed to support female urogenital health. The strains, originally licensed from Chr. Hansen (now Novonesis), are known for their ability to migrate from the gastrointestinal tract to the vaginal canal. Once colonized, they help restore the natural vaginal flora by producing lactic acid, which maintains an acidic environment, and secreting biosurfactants that inhibit the adhesion and biofilm formation of pathogens such as *Gardnerella vaginalis*. It is primarily utilized as an adjuvant treatment to prevent the recurrence of bacterial vaginosis (BV) and to manage vaginal dysbiosis.
- Brand names
- Umeta-Miyue优美达·蜜悦
- Other names
- Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14GR-1 + RC-14
Beyond the preview
Go deeper on Umeta-Miyue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Umeta-Miyue.